Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Strategy for Treatment of Atherosclerotic Cardiovascular Disease - Comparison of Clopidogrel-based Antiplatelet Agent Treatment Versus Aspirin Plus Low Dose Rivaroxaban Therapy

NCT07796217 is registered in ClinicalTrials.gov with Seoul National University Bundang Hospital as lead sponsor.

NCT NCT07796217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07796217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Strategy for Treatment of Atherosclerotic Cardiovascular Disease - Comparison of Clopidogrel-based Antiplatelet Agent Treatment Versus Aspirin Plus Low Dose Rivaroxaban Therapy
Lead sponsor
Seoul National University Bundang Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
November 15, 2023
Completion date
December 31, 2027
Enrollment
2,758 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bleeding, cardiac event, coronary artery disease, peripheral artery disease